Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
|Articles|August 1, 2007
August 2007 Oncology News International
Advertisement
Focus on Colon Cancer
Focus on Oncology Nursing
Focus on Breast Cancer
Focus on Prostate Cancer
Focus on Hematology
Focus on Lung Cancer
Focus on Pain
Industry Watch
Advertisement
Related to this article
“Those of us who work with NK cells have no doubt that they are incredibly powerful at killing cancer cells,” said Veronika Bachanova, MD, PhD.
Tyler Wilhite, MD, discusses expanding a radiation oncology program to also utilize low-dose radiation therapy for benign diseases.
Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.
Jeffrey V. Matous, MD, explains why ramantamig’s MRD negativity rates are clinically significant in relapsed/refractory myeloma.
In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.
Experts in multiple myeloma discussed long-term MAIA and CEPHEUS trial data and their implications for daratumumab-based regimens in newly diagnosed disease.
Adjuvant radiotherapy significantly reduced meningioma recurrence or death vs observation in grade 2 atypical meningioma after complete surgical resection.
Advertisement
Advertisement
Trending on CancerNetwork
1
Building a Low-Dose Radiation Therapy Program for Benign Disease
2
Clinical Applications and the Future of Remote Endovascular Procedures
3
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
4
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
5